anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: Obesity is a growing healthcare challenge worldwide and a significant risk factor for liver failure as seen with non-alcoholic steatohepatitis (NASH). Combining metabolic-bariatric surgery (MBS) with liver transplantation (LT) appears as attractive strategy to treat both, the underlying liver disease and obesity. However, there is an ongoing debate on best timing and patient selection. This survey was designed to explore the current treatment practice for patients with NASH and obesity worldwide.
METHODS: A web-based survey was conducted in 2022 among bariatric and LT surgeons, and hepatologists from Europe, North and South America and Asia.
RESULTS: The survey completion rate was 74% (145/196). The average respondents were 41-50 years (38%), male (82.1%) and had >20 years of clinical experience (42.1%). Centres with a high LT-caseload for NASH were mainly located in the USA and United Kingdom. Almost 30% have already performed a combination of LT with MBS and 49% plan to do it. A majority of bariatric surgeons prefer MBS before LT (77.2%), whereas most of LT surgeons (52%) would perform MBS during LT. Most respondents (n = 114; 80%) favour sleeve gastrectomy over other bariatric techniques. One third (n = 42; 29.4%) has an established protocol regarding MBS for LT candidates.
CONCLUSION: The most experienced centres doing LT for NASH are in the USA and United Kingdom with growing awareness worldwide. Overall, a combination of MBS and LT has already been performed by a third of respondents. Sleeve gastrectomy is the bariatric technique of choice-preferably performed either before or during LT.
The invention relates to steerable object synthesis in 3D medical images with structured image decomposition. Systems and methods for generating a composite image are provided. An input medical image patch, a segmentation mask, a vector of appearance-related parameters, and a manipulatable attribute are received. A synthesized medical image patch including a synthesized nodule is generated based on the input medical image patch, the segmentation mask, the vector of appearance-related parameters, and the manipulatable attributes using the trained object synthesis network. The synthesized nodules are synthesized according to the manipulatable attribute. The synthesized medical image patch is output.
<P>PROBLEM TO BE SOLVED: To provide an immunostimulator which can be safely used over a long period of time, derived from naturally occurring substances, has few side effects and prevents allergic symptoms of pollinosis, atopic allergy, etc. and carcinogenesis by regulation of immune balance and immunostimulatory action.  <P>SOLUTION: The immunostimulator includes a ground product or extract of a Salacia spp. plant. The Salacia spp. plant is preferably at least one plant chosen from Salacia reticulata, Salacia oblonga and Salacia chinensis. The immunostimulator is preferably administered as food or a pharmaceutical product.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The mechanisms that underlie variation in cholesterol efflux are unknown. There is a critical need to identify factors that regulate cholesterol efflux to effectively advance the clinical development of cholesterol efflux as both a risk prediction marker and as a target of therapy. The investigator's long-term goal is to determine whether modulating cholesterol efflux prevents or reverses cardiovascular disease. The overall objective of this study is to systematically create a family pedigree and biobank repository of blood and DNA from participants from the Dallas Heart Study with extreme low or high cholesterol efflux, with the specific aims of : 1) determining the heritability of and genomic factors associated with cholesterol efflux, and 2) identifying the protein and lipid signature of extreme low and high cholesterol efflux in a sex- and ethnicity-specific manner. The investigator's central hypothesis is that a combination of genetic variation in lipid transporters as well as proteins and lipids will be most strongly correlated with variation in efflux.

DHS probands and their relatives (parents, siblings, adult children, grandparents, aunts/uncles, cousins) with extreme low or high cholesterol efflux will be recruited to establish a prospective family pedigree cohort and understand the heritability of extreme cholesterol efflux. Investigators will collect the following information from all participants: demographics, health history, lifestyle measures, and medications. Blood will be collected on-site by venipuncture and plasma, serum, and cells will be stored at -80o Celsius. All efflux measurements will be completed in the investigator's laboratory.
Of the total number of subjects in clinical studies of EDECRIN/SODIUM EDECRIN, approximately 224 patients (21%) were 65 to 74 years of age, while approximately 100 patients (9%) were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. (See WARNINGS.)

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CONTRAINDICATIONS.)
Soft contact lenses (CL) are the most common CL modality with over 140 million users world. Despite many improvements in CL materials and solutions, the advent of daily disposable CLs, and the addition of rewetting drops to improve CL comfort, research has shown that between 21% to 64% of CL wearers permanently discontinue CL use because of eye discomfort. Contact Lens Discomfort (CLD) as defined by the Tear Film and Ocular Surface Society (TFOS) "is a condition characterized by episodic or persistent adverse ocular sensations related to lens wear, either with or without visual disturbance, resulting from reduced compatibility between the CL and the eye's environment, which can lead to decreased wearing time and discontinuation of CL wear." TFOS further states that CLD is a multifactorial condition that stems from both CL (e.g., material design, fit, care system) and environmental factors (patient factors, medication compliance, external environmental factors, ocular environment). While environmental factors related to the patient such as age and sex are inherent, rewetting drops or artificial tears can be used to treat tear film deficiencies associated with CLD. The U.S. Food \& Drug Administration (FDA) defines rewetting/lubricating drops as "an in-eye solution for use with CLs" that contains "one or more active ingredients (e.g., ophthalmic demulcents) in sufficient concentration to alleviate symptoms of discomfort from CL wear by physical means." Clinicians also commonly use artificial tears off label for treating CLD and the dry eye associated with CLs because artificial tear formulations have the potential to outperform CL rewetting drops. The FDA separately classifies artificial tears as topical drops that contain specific types of demulcents or emollients. While off-label, McDonald et al. have previously shown that using a common artificial tear, Systane Ultra, before and after CL use is an effective means for treating daily disposable CL wears who have CLD. Recently, a new formulation of artificial tears, Systane Complete, was released to the market. Systane Complete is a unique formulation that has combined elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for evaporative dry eye) to create an artificial tear with an indication for aqueous deficient, evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the Research Goal of this study is to determine in a randomized clinical trial if Systane Complete is able to effectively improve the symptoms of CLD suffers.
A method includes identifying a stoma at an initial position. The method also includes identifying one or more portions of a leak originating from the stoma at an initial position. The method further includes applying a composition to the one or more portions of the leak. The composition includes bentonite clay and guaran. The bentonite clay and guaran enable the composition to soak the one or more portions of the leak, and prevent the one or more portions from continuing to flow. The method also includes determining whether additional portions of the leak have originated from the stoma after the composition has been applied.
The control of posture is guided by the integration of sensory information. Because blind individuals cannot apply visual information to control posture as sighted individuals do they must compensate by the remaining senses. We therefore hypothesize that blind individuals alter their brain activation in the sensorimotor cortex during postural control to compensate for balance control without vision by the increased integration of somatosensory information. Ten blind and ten sighted (matched) individuals controlled posture during conditions with (I) eyes closed / open, and (II) stable / unstable surface conditions. Postural sway was recorded by applying a pressure distribution measuring plate. Brain activation was collected by functional Near InfraRed Spectroscopy (fNIRS) above motor-sensory cortices of the right and left hemispheres. Blind individuals showed significantly increased postural sway when balancing with open eyes on an unstable surface and when compared to sighted individuals. Whereas blind individuals showed significantly increased brain activation when balancing with open eyes on stable and unstable surface conditions, sighted individuals increased their brain oxygenation only during closed eyes and unstable surface conditions. Overall conditions, blind individuals presented significantly increased brain activation in two channels of the left and right hemispheric motor-sensory cortex when compared to sighted individuals. We therefore conclude that sighted individuals increase their brain oxygenation in the sensorimotor cortex during postural control tasks that demand sensory integration processes. Blind individuals are characterized by increased brain activation overall conditions indicating additional sensory integration during postural control. Thus, the sensorimotor cortex of blind individuals adapts to control posture without vision.
This invention provides novel replication-defective adenoviral vectors comprising an adenoviral genome in which the protein IX gene, preferably under the control of its own promoter, is in an inverted orientation relative to the direction of transcription of the native protein IX gene at a location where the protein IX gene normally resides, for production of replication-competent adenovirus (RCA) free, or substantially RCA-free, adenovirus preparations. Said vector preferably encodes a gene of interest. The invention relates to viral particles, host cells and compositions comprising said adenoviral vector. This invention further relates a method for propagating adenovirus preparations, free, or substantially free, of replication-competent adenovirus (RCA) particles, from host cells comprising vectors of this invention, for use to treat a subject suffering from a disease or disorder or to prevent a subject from getting a disease or disorder, such as cancer. The invention also provides methods of treating such subjects and methods of prophylactically treating unaffected subjects. This invention further provides for vaccine compositions comprising the novel replication-defective adenoviral vectors of the present invention.
1. Pressurized metered dose inhalers containing a solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterized in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodized aluminium or are lined with an inert organic coating, selected from perfluoroalkoxyalkane, epoxy-phenol resin or fluorinated-ethylene-propylene polyether sulfone, said material preventing the chemical degradation of the active ingredient with proviso that if active ingredient is fluonizonide, inert coating is not epoxy l resin. 2. Pressurized metered dose inhalers according to claim 1, characterized in that the active ingredients are selected from beta2 agonists, steroids or anti-cholinergic agents and their combinations, with proviso that if active ingredient comprises fluonizonide, inert coating is not epoxy resin. 3. Pressurized metered dose inhalers according to claim 2, characterized in that the active ingredient is ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide and epimers thereof. 4. Pressurized metered dose inhalers according to any of claims from 1 to 3, characterized by containing a lowvolatility component selected from glycerol, polyethylene glycol and isopropyl myristate. 5. Pressurized metered dose inhalers according to any of claims from 1 to 4, characterized in that the co-solvent is ethanol. 6. Pressurized metered dose inhalers according to any of claims from 1 to 5, characterized in that the propellant is selected from HFA 227, HFA 134a and their mixtures. 7. Pressurized metered dose inhalers according to any of claims 1 to 7, characterized in that part or all of the internal surfaces are coated with an epoxy phenol resin. 8. Pressurized metered dose inhalers according to any of claims 1 to 6, characterized in that part or all of the internal surfaces consist of anodized aluminium. 9. Pressurized metered dose inhalers according to any of claims 1 to 8, characterized in that the active ingredient is budesonide or dex-budesonide, and co-solvent is ethanol.
Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
PROBLEM TO BE SOLVED: To provide a pharmaceutical preparation that contains an unsaturated fatty acid and is excellent in endermic absorption with side-effects reduced. SOLUTION: This skin preparation contains a triglyceride represented by the formula (one or two of R1 , R2 and R3 are the residues of long-chain unsaturated fatty acids and the remaining(s) is the residue of middle-chain fatty acid). In a preferred embodiment, a triglyceride represented by the formula (one of R1 , R2 and R3 is a residue of long-chain unsaturated fatty acid and the remainings are the residues of middle-chain fatty) is contained as an active ingredient. The long-chain unsaturated fatty acid is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid, α-linolenic acid, γ-linolenic acid, linoleic acid, dihomo-γ-linolenic acid. In the most preferred embodiment, they are a residue of eicosapentaenoic acid or a residue of docosahexaenoic acid.  The triglyceride is prepared by using the long-chain unsaturated acid and/or its derivative of >=90%, more preferably >=95% purity.
After the lungs are explanted from the recipient donor, they will be connected to the "Angel Cooler" via a tracheostomy tube or special adaptor to assess the function of this device in providing cooling oxygen and positive pressure to keep the lungs inflated while on the back table. The lungs will be hooked up to the cooling machine for 15-20 minutes. During this time, investigators will monitor the airway temperature, pressure and oxygen concentration continuously during the entire preservation time. Once these measures are obtained and synced to a corresponding computer, investigators will then disconnect the lungs from the device and continue the standard procedure of sending them to pathology where they will be discarded per usual in lung transplantation.
PURPOSE: A capsule formulation with stabilized whitening ingredients and cosmetic composition for skin whitening is provided to effectively block swelling of a whitening agent due to water and surfactant. CONSTITUTION: A capsule formulation for whitening with whitening ingredients contains a lipid lamella layer and a polymer layer. The lipid lamella layer exists on a nucleating agent and contains ceramide, phospholipid, and whitening ingredients. The ceramide is natural ceramide or ceramide analogue. The phospholipid is selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, and phosphatidic acid. The whitening ingredients is selected from the group consisting of ellagic acid, Rabdosia Rubescens extract, Saxifraga furumiii extract, grape extract, Scutellariae radix extract, and acetyltetrapeptide-11.
PROBLEM TO BE SOLVED: To provide a care support system, a control method and a program capable of outputting a future care plan by using care records of a care receiver.SOLUTION: A helper inputs vital data such as a body temperature and a blood pressure that the helper has measured at the time of caring for a care receiver to a tablet terminal 5A. Mental and physical external data such as the movements of hands and legs and conversations of the care receiver are input to a management terminal 4. Input data of the tablet terminal 5A and the mental and physical external data input to the management terminal 4 are stored in a Web server 2. An application server 3 analyzes care information transmitted from a Web server 2, and generates care plan information on the basis of the analysis result. The generated care plan information is transmitted from the application server 3 via the Web server 2 and the management terminal 4 to the tablet terminal 5A. The helper can provide an appropriate care service to the care receiver by caring for the care receiver in accordance with the care plan information.SELECTED DRAWING: Figure 1
The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
HIV nurses based at Group B facilities will be trained on the 5As counseling approach strategy (Ask, Assess, Advise, Assist, and Arrange) and referral for the participants to the health center. However, they will not receive practice facilitation from the POFs. Participants attending PHC randomized to Group B will receive standard care offered by the facility.
Until now, in trials it is common to stop therapy when progressive disease occurs; RECIST criteria are used, in which progressive disease is defined as \>20% increase of the sum of the longest diameter of the lesions, or occurence of new lesions. However, angiogenesis inhibitors have a rather cytostatic than cytotoxic effect compared to chemotherapeutics, as a result of which less frequently reduction of tumor volume is being seen.

Often in the centre of the lesion necrosis is shown. Sometimes accompanied with edema; so even tumor volume increase can be the result without real progression being the case. Recently, in our clinic, we found a number of patients, treated with oral angiogenesis inhibitors, a remarkable quickening of progressive disease and complaints after stopping this treatment. Reintroduction of the same or another type of angiogenesis inhibitor subsequently lead to a new stabilization. The causality of this phenomenon is unknown. Perhaps that the inhibitory effect of the angiogenesis is not fully exhausted at the moment that progressive disease on CT is observed. An alternative explanation is contra reaction of longterm angiogenetic inhibition through upregulation of proangiogenic factors with subsequent vascular expansion and edema. This study means to gain more insight information about the optimal treatment policy when progressive disease is found in patients treated with oral angiogenesis inhibitors. Because of the increase of patients that is being treated with these products, both in trials as in daily clinical practice, this is important to investigate.
Lack of data is one of the biggest hurdles for rare disease research using deep learning. Due to the lack of rare-disease images and annotations, training a robust network for automatic rare-disease image segmentation is very challenging. To address this challenge, few-shot domain adaptation (FSDA) has emerged as a practical research direction, aiming to leverage a limited number of annotated images from a target domain to facilitate adaptation of models trained on other large datasets in a source domain. In this paper, we present a novel prototype-based feature mapping network (PFMNet) designed for FSDA in medical image segmentation. PFMNet adopts an encoder-decoder structure for segmentation, with the prototype-based feature mapping (PFM) module positioned at the bottom of the encoder-decoder structure. The PFM module transforms high-level features from the target domain into the source domain-like features that are more easily comprehensible by the decoder. By leveraging these source domain-like features, the decoder can effectively perform few-shot segmentation in the target domain and generate accurate segmentation masks. We evaluate the performance of PFMNet through experiments on three typical yet challenging few-shot medical image segmentation tasks: cross-center optic disc/cup segmentation, cross-center polyp segmentation, and cross-modality cardiac structure segmentation. We consider four different settings: 5-shot, 10-shot, 15-shot, and 20-shot. The experimental results substantiate the efficacy of our proposed approach for few-shot domain adaptation in medical image segmentation.
The invention discloses an ozagrel sodium drug combination for injection. The ozagrel sodium injection solution consists of ozagrel sodium, mannitol and anhydrous sodium carbonate, wherein each piece contains 20-80 mg of ozagrel sodium, 20-80 mg of mannitol and 5-15 mg of anhydrous sodium carbonate. The drug combination is prepared by a method comprising the following steps: taking a recipe quantity of injection water, adding the mannitol and the anhydrous sodium carbonate and stirring until the mannitol and the anhydrous sodium carbonate are dissolved; adding the ozagrel sodium, and stirring until the ozagrel sodium is fully dissolved; regulating a pH value between 7.7 and 8.7; adding medicinal carbon and stirring; leaching, replenishing the injection water to a full quantity and uniformly mixing; finely filtering; encapsulating; freeze-drying; inspecting with a light; and warehousing to obtain the ozagrel sodium drug combination. The ozagrel sodium drug combination has good stability. The production rate of the product is increased, the cost is lowered, and industrialization is realized. The drug combination can be better applied in clinic and has more remarkable advantages.